RNA repair restores hemoglobin expression in IVS2-654 thalassemic mice by Svasti, S. et al.
RNA repair restores hemoglobin expression in
IVS2–654 thalassemic mice
Saovaros Svastia,b,1, Thipparat Suwanmaneea,1, Suthat Fucharoenb, Hong M. Moultonc, Michelle H. Nelsonc,
Nobuyo Maedad, Oliver Smithiesd,2, and Ryszard Kolea,c,2
aDepartment of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599; bThalassemia Research
Center, Institute of Science and Technology for Research and Development, Mahidol University, Salaya Campus, Nakornpathom 73170, Thailand; cAVI
BioPharma, Corvallis, OR 97333; and dDepartment of Pathology, University of North Carolina, Chapel Hill, NC 27599
Contributed by Oliver Smithies, December 8, 2008 (sent for review June 3, 2008)
Repair of -globin pre-mRNA rendered defective by a thalassemia-
causing splicing mutation, IVS2–654, in intron 2 of the human
-globin gene was accomplished in vivo in a mouse model of
IVS2–654 thalassemia. This was effected by a systemically deliv-
ered splice-switching oligonucleotide (SSO), a morpholino oli-
gomer conjugated to an arginine-rich peptide. The SSO blocked the
aberrant splice site in the targeted pre-mRNA and forced the
splicing machinery to reselect existing correct splice sites. Repaired
-globin mRNA restored significant amounts of hemoglobin in the
peripheral blood of the IVS2–654 mouse, improving the number
and quality of erythroid cells.
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One of the most common inherited diseases, -thalassemia,is caused by defects in the -globin gene that affect
production of -globin, a subunit of hemoglobin (1). Current
therapy consists of frequent blood transfusions combined with
iron chelation (2). The only cure, bone marrow transplantation,
is limited by the scarcity of suitable histocompatible donors (3).
Although more than 200 mutations cause the disease, some of
the most common ones induce aberrant splicing of -globin
pre-mRNA, interfering with proper translation of -globin
protein. The IVS2–654 (C  T) mutation creates an aberrant 5
splice site and activates a cryptic 3 splice site within intron 2 of
the -globin pre-mRNA, leading to retention of the intron
fragment in the spliced mRNA even though the correct splice
sites remain undamaged and potentially functional (Fig. 1A) (4).
The retained fragment prevents proper translation of -globin,
leading to hemoglobin deficiency and -thalassemia. The IVS2–
654 mutation is a common cause of thalassemia in Thailand and
other countries of Southeast Asia (5). Work in this laboratory
showed that splice-switching oligonucleotides (SSOs), which
block aberrant splice sites in IVS2–654 and other pre-mRNAs
(IVS1–5, IVS1–6, IVS1–110, IVS2–705, and IVS2–745) as well
as in the coding sequence (HbE) of the -globin gene, force the
splicing machinery to reselect the existing correct splice sites,
repairing the splicing pattern of -globin pre-mRNA. This
repair, which restores production of correctly spliced -globin
mRNA and protein, was accomplished in several in vitro systems
and ex vivo in erythroid progenitor cells from thalassemic
patients (6–12). In this study, we investigated the effectiveness in
thalassemic splicing correction of a modified morpholino
oligomer, SSO 654-P005, in a mouse model of IVS2–654
-thalassemia.
Results and Discussion
To be effective in splicing repair, SSOs must hybridize tightly to
the targeted splicing elements, such as aberrant splice sites, and
prevent their recognition by the splicing factors. Furthermore,
the resulting double-stranded structures must not be recognized
by RNase H, which degrades RNA in RNA-DNA duplexes (13).
These conditions are satisfied in cell culture and in vivo by
modified oligomers with various backbones, including 2-O-
methoxyethyl phosphorothioate (MOE), locked nucleic acid
(LNA), peptide nucleic acid conjugated with four lysines (PNA-
4K), and phosphorodiamidate morpholino oligomers (14–16).
However, MOE and LNA SSOs were ineffective at correcting
aberrant splicing of IVS2–654 pre-mRNA when delivered ex
vivo to cultured erythroid progenitor cells from IVS2–654
murine bone marrow cells (data not shown). PNA-4K and
morpholino SSOs had only a modest effect at 45 M on
IVS2–654 pre-mRNA splicing in these cells (Fig. 1 B and C).
Clearly, cell uptake of these oligonucleotides followed by trans-
location from the cytoplasm to the nucleus, the site of splicing,
was limited. In this investigation, we found that a morpholino
oligomer conjugated to a cell-penetrating peptide P005 (SSO
654-P005; in short is SSO P005) (17) was effective in a previously
developed cell-based assay (18) and also in IVS2–654 pre-
mRNA repair in cultured murine erythroid progenitor cells.
The shift in splicing from aberrant to correct was almost
complete at 15 M SSO 654-P005 (Fig. 1D). This SSO was then
used for treatment of the previously generated thalassemic
IVS2–654 mice (19). These mice are heterozygotes with 1 human
IVS2–654 thalassemic -globin gene ‘‘knocked-in’’ to replace 2
cis--globin genes that code for murine adult -globin (-major
and -minor). The average level of total hemoglobin in these
mice is 11.7  0.5 g/dL (n  18). Despite a relatively high level
of total hemoglobin, these mice exhibit thalassemic character-
istics, including abnormal hematological indices, splenomegaly
and iron deposits in advanced age. This phenotype is somewhat
different from that of humans, who, as heterozygotes, are
essentially symptom-free but similar to other thalassemic mouse
models. IVS–654 mice produce reduced amounts of murine
-globin chains, leading to imbalance of - to -globin produc-
tion, which may be damaging to erythroid cells (19 and refer-
ences cited therein).
The IVS2–654 mice were treated with SSO 654-P005, deliv-
ered intravenously at 25 mg/kg with 4 once-daily injections
followed by a 3-day break for 3 weeks (Materials and Methods).
This treatment restored correctly spliced human -globin
mRNA in the peripheral blood up to 12% (Fig. 2A). The
scrambled negative control SSO, P005 scr SSO, yielded no
correction (Fig. 2 A, lanes 6 and 7). Quantification of in vivo
mRNA repair in the peripheral blood of SSO 654-P005-treated
mice (n  3–4) using RT-quantitative real-time PCR (qPCR)
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showed that the correct human -globin mRNA was restored up
to 6-fold after treatment (Fig. 2B). The newly repaired -globin
mRNA was properly translated in circulating red blood cells
(RBCs) and consistently yielded chimeric mouse-human hemo-
globin (m2h2), which reached 1–5% of the total in treated
mice (n  9; Fig. 2C).
Analysis of RBCs was carried out on mice 834, 835, 843, and
845. Despite a relatively low level of hemoglobin expression (Fig.
2C, lanes 4–7), improvement in RBC morphology was clearly
detectable. Abnormal RBCs, including fragmented cells and
those with abnormalities in shape and size (poikilocytosis and
anisocytosis), were much less evident, indicating more effective
erythropoiesis and less extravascular hemolysis. Concomitantly,
the number of normal RBCs increased by 10% (Fig. 3 A and
B). These results were consistent with a detectable and statis-
tically significant reduction of the red cell distribution width
(RDW), an indicator of red cell heterogeneity and increase in
total hemoglobin level in the peripheral blood (n  5; Fig. 4) of
treated mice 5, 6, 13, 995, and 996 (Fig. 2C, lanes 8–12). In each
mouse, the trend was reduced RDW and increased hemoglobin
level, whereas in saline-treated mice, this trend was not ob-
served. It is also noticeable that in mice with a lower initial
hemoglobin level (11 g/dL), the increase was more pronounced
(Fig. 4B).
The latter observation was confirmed in a single IVS2–654
mouse encountered in the colony with a low total hemoglobin
level of 7.5 g/dL. We took advantage of this mouse and subjected
it to an extended course of SSO 654-P005 treatment delivered by
i.p. injection at 50 mg/kg on a schedule 4 days on and 3 days off
for 6 weeks. In this particular experiment, the SSO treatment led
Fig. 1. (A) Splicing of IVS2–654 -globin pre-mRNA and its repair by SSO.
Boxes, exons; solid lines, introns and correct splicing pathway; dotted lines,
aberrant splicing pathway. Thick bar, SSO; arrows, primers used in the RT-PCR
assay. The length (in nucleotides) of RT-PCR products representing aberrantly
(ab) and correctly (c) spliced mRNAs is shown. (B–D) Restoration of correctly
spliced human -globin mRNA in cultured erythroid progenitor cells. Cells
were isolated from the bone marrow of IVS2–654 mouse and treated with
PNA-4K (B), morpholino (C), and SSO P005 (D) SSOs. Treatment was by free
uptake (FU) of SSO from the culture medium. SSO concentrations and the time
of cell harvest are indicated. Total cellular RNA was analyzed by RT-PCR. N,
RNA from normal human blood.
Fig. 2. Repair of human -globin mRNA in vivo in IVS2–654 thalassemic mice
by i.v. injections of SSO P005. (A) Conventional RT-PCR of total RNA from SSO
P005-treated mice. RNA was isolated from peripheral blood. Lane 1, normal
human blood (N); lane 2, prebleed; lanes 3–5, blood collected after 4, 8, and
12 SSO injections, respectively; lanes 6–7, blood collected from IVS2–654 mice
treated with negative control P005 scr SSO; lane 8, no reverse transcription
(NRT); lane 9, no template control (NTC). Days of bleeding and percentages of
correctly (c) spliced mRNA compared with aberrantly (ab) spliced mRNA are
indicated. No product was detectable without the RT step or in the absence of
mRNA template. (B) Quantification of RNA repair by RT-qPCR. The mice were
prebled and intravenously injected with 4 (n  4), 8 (n  3), and 12 (n  3) doses
of SSO P005. Total RNA from blood collected before [day (d) 0] and after every
4 SSO injections (d 5, 12, and 19) was analyzed. Data presented as mean  SD.
P values 0.05 were determined by one-way ANOVA. Asterisks denote sta-
tistically significant difference. The correctly spliced human -globin mRNA
was not detectable (ND) in prebled samples because the probe was designed
to hybridize exclusively to the correct human -globin mRNA (Materials and
Methods). (C) Chimeric mouse-human hemoglobin (m2h2) generated by
SSO P005 treatment. IVS2–654 mice (n  9) were dosed intravenously with SSO
P005 for 3 weeks on a schedule: 4 once-daily injections and 3 days off. (Top)
Hemoglobin levels were assayed by immunoblots with anti-human -globin
antibody of cellulose acetate electrophoregrams. Blood samples were taken
before injections (lanes 1–3) and 1 day after the last injection (d 19) (lanes 4–12).
(Bottom) Immunoblots were quantified using ImageQuant TL software.
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to marked elevation of hemoglobin from 7.5 to 10.7 g/dL and of
hematocrit levels from 19.9 to 29% (data not shown). Although
a single mouse experiment has no statistical value, it further
supports the notion that prolonged SSO treatment may be
clinically valuable. It also suggests that at low hemoglobin levels,
the response may be more robust than in mice with relatively
high levels of hemoglobin. Thus, the nature of the model could
have contributed to the modest response to treatment shown in
Fig. 4.
This treatment was terminated at day 19 because we were
unable to inject SSO 654-P005 into scarred tail veins reliably.
Note that mouse RBCs have a lifespan of 60 days (20). Thus,
during the period of injections, even if the restoration of splicing
and hemoglobin production were 100% effective, only one-third
of the existing RBCs, lacking additional hemoglobin, could have
been replaced. Nevertheless, with prolonged SSO treatment, the
fraction of healthy RBCs should continue to increase in the cell
population in peripheral blood and further improve the overall
hematological manifestations, including elevation of the hemo-
globin and hematocrit levels.
We investigated the toxicity of SSO 654-P005 in IVS2–654
mice (n  4) that received 16 SSO injections. Standard bio-
chemical tests indicate no apparent liver or kidney toxicity (Fig.
5 A–D), nor was there any weight loss (Fig. 5E). To evaluate the
primary inflammatory response that the treated mice might
develop against the peptide-conjugated SSO 654-P005, we per-
formed RT-qPCR to determine the change in transcriptional
level of the IFN- and IL-12a cytokines after every 4 i.v.
injections of the SSO at 25 mg/kg. The results shown in Fig. 5F
indicate no significant change in the mRNA level of both
cytokines. Furthermore, we found no significant change in IL-12
cytokines in SSO 654-P005-primed mice when they were chal-
lenged with the SSO 1 month after treatment, indicating that the
SSO did not trigger the immune functioning cells to release their
inflammatory cytokine (Table 1). More importantly, we did not
detect SSO 654-P005-specific antibodies in the sera, indicating
that the SSO did not induce a humoral immune response (data
not shown). Finally, we investigated the cellular immune re-
sponse of the lymphocytes from the treated mice to indicate
whether they form memory cells that can recognize the SSO. To
this end, we used the enzyme-linked immunosorbent spot assay
(ELISPOT) to monitor the IFN- production and SSO 654-
P005-specific antibody induction in the cultured lymphocytes
that ex vivo encountered the SSO 654-P005. We found that the
SSO challenge did not stimulate the lymphocytes to produce
either IFN- or the antibody (data not shown).
We have found that repair of splicing-defective thalassemic
pre-mRNA and concomitant production of adult hemoglobin
(HbA) can be accomplished ex vivo in erythroid progenitor cells
from thalassemic patients treated with SSOs with modified
backbones (10, 11), including peptide-conjugate morpholino,
SSO 654-P005 (data not shown). Thus, this treatment is com-
patible with and effective in the human cells that will constitute
its target in the clinic.
We have shown by several measures that SSO 654-P005
improved the efficiency of erythropoiesis and concomitant
morphology of erythrocytes in the peripheral blood of treated
thalassemic mice. The SSO-induced mRNA repair, production
of human -globin, more efficient cell hemoglobinization, in-
creased number of improved mature erythrocytes, and small
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Fig. 3. Improvement of RBC morphology after SSO P005 treatment. (A) Wright-Giemsa-stained peripheral blood smears of IVS2–654 mouse were prepared
before [day (d) 0] and after 12 i.v. injections of SSO P005 (d 19). WT, wild-type mouse. (B) Differential count of abnormal (ARBC), target (TRBC), hypochromic
(HRBC), and normal (NRBC) RBCs. Blood smears before and after 12 i.v. injections of SSO P005 from IVS2–654 mice (n  4) were stained with Wright-Giemsa. Three
different field images were taken from each smear and used for the differential RBC count. Data are presented as mean  SD. The difference between the
numbers of NRBCs before and after SSO P005 treatment is 10% but not significant (P  0.06; one-tailed Wilcoxon signed test).











increase in the total level of hemoglobin were consistently
evident after treatment, confirming that it had beneficial effects.
The fact that the effects were modest may reflect the nature
of the model more than the performance of the oligonucleotide.
The IVS2–654 mice are heterozygotes; therefore, at best, SSO
treatment may only increase the hemoglobin levels by no more
than one-half. Because the duration of the experiment was 19
days (i.e., one-third of the murine erythrocyte 60-day lifespan),
the effect is reduced to 15%, assuming complete IVS2–654
repair in all targetable erythroid progenitor cells. SSO effec-
tiveness less than 100%, which is to be expected, brings the
results within statistical error, which, in our hands, was about
10% for hemoglobin and hematocrit assay. Furthermore, these
calculations do not take into account that IVS2–654 gene may
be expressed at a level that produced less mRNA, and hence
-globin, than the combined output of eliminated mouse
-major and -minor genes. Another contributing factor to the
poor response of the model appears to be the relatively high (11.7
g/dL) preexisting level of hemoglobin in untreated thalassemic
mice. This is supported by the observation that in a mouse that
had low hemoglobin (i.e., more pronounced anemia) and was
treated with SSO 654-P005 for 6 weeks, the response was much
more robust. Because the SSO is effective in human cells, the
approach may be applicable to patients with IVS2–654/HbE
thalassemia who do not produce functional HbA.
One notes that in transfused thalassemics, the hemoglobin
level rises to about 20–30% and is clinically sufficient, whereas
carriers with 50% hemoglobin are essentially asymptomatic. The
results of this work already showed changes in blood morphol-
ogy; the improvements need not be dramatic to achieve clinical
significance. It is possible that continuous i.v. injections, impos-
sible in mice for technical reasons, may be sufficient. The dose
of SSO 654-P005 appears high at 25 mg/kg. However, if, as is
frequently the case, dosing of morpholino oligonucleotides is
scaled between mice and humans by mg/m2, the human equiv-
alent dose would be 2 mg/kg, which translates into 100 mg per
dose for a 50-kg child, a likely patient.
Recent reports showed in vivo restoration of chloride channel
function in myotonic dystrophy (21), factor VIII in a model of
hemophilia (22), and dystrophin in the mdx mouse model of
Duchenne muscular dystrophy (23–25) by oligonucleotide-
induced modulation of splicing, an approach discovered in the
Kole laboratory (6). These results, together with those reported
here, indicate that the splicing-mediated pre-mRNA repair is not
limited to a single disease. In fact, modulation of aberrant and
alternative splicing by antisense oligonucleotides is likely to be
useful in numerous indications, because 70% of human genes are
alternatively spliced, with a number of them associated with
cancer (26) and other diseases (27–29).
Materials and Methods
Oligonucleotides. The profiles of morpholino and PNA-4K oligonucleotides,
including their sequences, were reported elsewhere (11, 14, 15). The 18-mer
morpholino (5-GCTATTACCTTAACCCAG-3)-peptide-[(D)R(D)RRQRRKKRFFC]
conjugate (P005) antisense to the aberrant 5 splice site in the IVS2–654
-globin pre-mRNA was synthesized at AVI BioPharma. The peptide contained
2 D-amino acid arginines at its N terminus as indicated in the sequence. The
peptide was conjugated at the 5 end of the morpholino oligomer through a
noncleavable linker. The method for synthesis and purification of the conju-
Fig. 4. Blood analysis for red cell heterogeneity (A) and hemoglobin level (B).
Blood samples from IVS2–654 mice before (prebleed) and after treatment
with 12 i.v. injections of SSO P005 (n  5) were analyzed in Heska’s animal
blood counter. Asterisk indicates statistically significant (one-tailed Wilcoxon
signed test) difference between prebled and SSO P005-treated mice. (A and B)
P  0.03. (C and D) RDW and hemoglobin levels of WT mice (n  3) injected
with saline (mean  SD).
Fig. 5. Toxicity assay of SSO P005. Serum samples from IVS2–654 mice before
[day (d) 0] and after treatment with 16 i.v. injections (d 26) of saline (n  5) or
SSO P005 (n  4) were analyzed for (A) aspartate aminotransferase (AST, U/L),
(B) alanine aminotransferase (ALT, U/L), (C) blood urea nitrogen (BUN, mg/dL),
and (D) creatinine (CREA, mg/dL). (E) Body weights of the mice were recorded
before (d 0) and after every 4 i.v. injections (d 5, 12, 19, and 26) of saline (n 
5) or SSO P005 (n  4). (F) Quantification of cytokine mRNAs by RT-qPCR. The
peripheral blood RNAs from saline mice (n  3) and mice treated with 4 (n 
5), 8 (n  6), and 12 (n  4) injections of SSO P005 were analyzed for IFN- and
IL-12a mRNAs. Data presented as mean  SD.
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gate was described elsewhere (17). The SSO 654-P005 (lyophilized powder)
was dissolved in sterilized water and was further diluted with saline to the
desired concentration. The P005 scr SSO was used as negative control oligo.
Oligonucleotide Treatment
In Vitro. The oligonucleotides were tested ex vivo in IVS2–654 mouse erythroid
progenitor cells, which were plated 18 h before SSO treatment using a free
uptake technique as described (11). SSO 654-P005 concentrations were as
shown in Fig. 1.
In Vivo. All animal protocols used in this study were approved by the Institu-
tional Animal Care and Use Committee of the University of North Carolina. The
2-month-old IVS2–654 mice were weighed and prebled before i.v. (25 mg/kg)
or i.p. (50 mg/kg) injection with the SSO at a volume not exceeding 200 L. The
injections were by means of 3 weekly courses, once daily for 4 consecutive days
followed by a 3-day break. The i.p. injections were administered for 6 weeks
on the same schedule.
RNA Isolation and Quantitative RT-PCR Analysis of Human -Globin mRNA. Total
RNA from cultured cells was isolated using TRI Reagent (Molecular Research
Center). Blood RNAs were extracted using BD-Tri Reagent (Molecular Research
Center). Forend-pointRT-PCR,200ngoftheRNAsamplewassubjectedtoRT-PCR
using the Thermostable rTth Reverse Transcriptase RNA PCR Kit (Applied Biosys-
tems) with 0.2 Ci of [-32P]dATP (Fig. 1 B–D) or with 0.05 nmol Cy5-AP3-dCTP (GE
Healthcare) (Fig. 2A) per reaction. The RT step was carried out at 70 °C for 15 min,
followed by PCR at 95 °C for 1 min and 65 °C for 1 min for 22 cycles. The primers
used in RT-PCR assay were documented elsewhere (11). The RT-PCR products
shown in Fig. 1 B–D were separated on 7.5% nondenaturing polyacrylamide gel
and visualized by autoradiography. The RT-PCR products shown in Fig. 2A were
analyzed on 10% nonpolyacrylamide 1.0-mm  12-well 1 M Tris, 0.9 M Boric acid,
0.01EDTAgel (Invitrogen),andtheelectrophoresiswasconductedat190Vfor1h
40 min. The gels were scanned using a Typhoon 9400 scanner (GE Healthcare).
ImageQuant TL image analysis software (GE Healthcare) was used to quantify
spliced -globin mRNA correctly. For the RT-qPCR assay, up to 1 g of the RNA
samplewastreatedwith1UofRQ1RNase-freeDNase (Promega).Halfof theRNA
was used for first-strand cDNA synthesis utilizing a high-capacity cDNA RT kit
(AppliedBiosystems).One-tenthofthecDNAofeachsamplewasusedtoperform
qPCR using Taqman 2 universal PCR master mix (Applied Biosystems) together
with 5-GCAAGAAAGTGCTCG and 5-CAGCACACAGACCAG as human -globin
mRNA-specific forward and reverse primers, respectively. The 5FAM-AACT-
TCAGGCTCCTGGGCAA-TAMRA was used as a probe to detect the correctly
spliced human -globin mRNA. The qPCR of each sample was done in duplicate
on the ABI 7900HT fast real-time PCR system (Applied Biosystems). Data were
normalized to -actin that was simultaneously quantified, together with the
correct -globin mRNA in the same reaction, using 5-GCACCACACCTTCTAC,
5-GTCTCAAACATGATCTGG, and 5HEX-ACCGAGGCCCCCCTGAAC-TAMRA as
the forward and reverse primers and probe, respectively.
Detection of Chimeric Mouse-Human Hemoglobin. The chimeric hemoglobin
(m2h2) was detected using cellulose acetate electrophoresis followed by im-
munoblot analysis. The hemolysates were prepared by lysing the phosphate-
buffer saline-washed RBCs obtained from peripheral blood of mice before (day
0) and after 12 i.v. injections of SSO 654-P005 (day 19) using hemolysate reagent
(Helena Laboratories). The concentration of hemoglobin was determined by the
cyanmethemoglobin method (Randox Laboratories). An equal amount of hemo-
globin fromeachsample (OD0.17)was loadedontoTitan III-Hcelluloseacetate
membrane, followed by electrophoresis at 350 V for 25 min. The hemoglobin
proteins on cellulose acetate membrane were fixed using 0.5% Ponceau S,
followed by 5% (vol/vol) acetic acid. The immunoassay was performed using
mouse anti-human -globin chain antibody with cross-reactivity against mouse
-globin (1 g/L; 1:1,000) (Accurate) and ECL Plex goat anti-mouse IgG-Cy 3 (1
g/L; 1:1,500) (GE Healthcare) as primary and secondary antibodies, respec-
tively. The membranes were scanned using Typhoon 9400 with a setting for
optimal Cy 3 detection [PMT 500 V, green (532) laser, and 580 BP 30 Cy3 TAMRA
filter]. Quantification of chimeric hemoglobin was assessed by ImageQuant TL
software.
Hematological Analysis. Peripheral blood samples were collected from the
central tail artery, using heparinized microhematocrit capillary tubes, on day
0 (prebleed) and day 19 after 12 i.v. injections of SSO 654-P005. The complete
blood cell count was performed using Heska’s animal blood counter. Blood
smears were stained with Wright-Giemsa for morphologic red cell analysis.
Toxicity Studies of SSO 654-P005. Peripheral blood samples were collected from
the central tail artery immediately before (day 0) and after treatment with
16 i.v. injections of saline or SSO 654-P005 (day 26). The sera, obtained by
clotting the blood at room temperature for 30 min, followed by centrifuga-
tion at 15,000  g for 8 min, were subjected to liver and kidney function tests.
Aspartate aminotransferase, alanine aminotransferase, blood urea nitrogen,
and blood creatinine were analyzed using an automatic chemical analyzer
(VT250; Johnson & Johnson).
Immune and Inflammatory Response Assay. For the primary inflammatory
response study, the IFN- and IL-12a mRNAs from peripheral blood of control
mice (n  3) and mice treated with 4 (n  5), 8 (n  6), and 12 (n  4) i.v.
injections of SSO 654-P005 at 25 mg/kg were quantified by RT-qPCR using an
ABsolute SYBR green rox mix (ABgene), together with the SuperArray cyto-
kine-specific primers (SuperArray Bioscience Corporation). Results were nor-
malized to mouse -actin expression level.
In the humoral immune response study, the 2-month-old IVS2–654 mice were
given 12 i.v. injections of saline (n  3) and 12 doses (n  3) and 16 doses (n  2)
of SSO 654-P005. One month after the last treatment, mice were bled (preboost-
ing) and the saline-treated mice and the 2 mice of 12-dose P005 group were given
a single i.v. injection of saline, whereas 1 mouse of the 12-dose P005 group and
the 2 mice of 16-dose P005 group were boosted i.v. with a single dose of SSO
654-P005 at 25 mg/kg. The sera were collected at days 3, 7, and 28 after boosting
and analyzed for IL-12 levels using the Quantikine mouse IL-12 p70 immunoassay
(R&DSystems).Theremainingserawerediluted1:50 in5%(wt/vol) skimmedmilk
and tested for P005-specific antibody using standard ELISA.
For the cellular immune response study, IFN- and P005-specific antibody-
secreting ELISPOT assays were carried out. One million spleen lymphocytes from
mice treated 10 months earlier with 12 doses of saline (n  4) or SSO 654-P005 at
25 mg/kg (n  4) were cultured in the AIM-V medium (Invitrogen) containing 400
ng of the SSO for 22 h at 37 °C, 5% (vol/vol) CO2. After incubating with biotin-
ylated antibody and color development, the plates were scanned using a CTL
plate reader (CTL Analyzers, LLC). The spots were counted using ImmunoSpot
Software 1.7e (CTL Analyzers, LLC).
Statistical Analysis. The Wilcoxon signed test (one-tailed formulation) was
used to compare data from 2 groups. Data from at least 3 groups were
Table 1. Measurement of mouse serum IL-12 p70 (pg/mL)
Samples Preboosting Day 3 Day 7 Day 28
Sal  Sal (7*) 0.67 28.49 ND 0.41
Sal  Sal (14*) ND ND ND 0.21
Sal  Sal (998*) ND ND ND 1.8
SSO  Sal (5†) 5.94 1.25 4.77 3.3
SSO  Sal (13†) ND ND ND ND
SSO  SSO (6‡) ND 0.41 ND ND
SSO  SSO (995‡) ND ND ND ND
SSO  SSO (996‡) 2.42 30.84 1.55 2.72
*Saline-treated mice; boosted with saline.
†SSO 654-P005-treated mice; boosted with saline.
‡SSO 654-P005-treated mice; boosted with SSO 654-P005 at 25 mg/kg.
ND, not detectable.











compared using one-way ANOVA. Data with a P value 0.05 were considered
statistically significant.
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